Aspirin is used for pain relief and selected prescribed arterial clot prevention. Uses differ. Confidence in that distinction is high; comparative efficacy is not independently cleared. NHS purpose.
- Ask whether the prescription treats established vascular disease or considers a first event.
- A coated product still carries bleeding warnings.
- Severe bleeding or airway symptoms need urgent or emergency care.
- Do not give aspirin to children under 16 unless prescribed.
- Pregnancy and feeding need a professional plan.
Table of contents
- Evidence summary
- Aspirin names and formulations
- Platelets, pain and the limits of mechanism
- Primary versus secondary cardiovascular prevention
- Recovery, lifestyle and supplement claims
- ASCEND and ASPREE: original methods and funding
- Bleeding, allergy and emergency warning signs
- Interactions, painkillers and duplicate ingredients
- Children, pregnancy and feeding
- Taking aspirin and procedures
- Human evidence limits and reporting concerns
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical descriptions, care guidance and independently established treatment outcomes have different evidentiary roles. The table identifies what the reviewed sources can support and which financial or clinical questions remain unresolved.
| Question / approach | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Uses | NHS; selected UK/US records | Public interests unclosed; commercial labels Tier 4/D | Clinical context; verify preparation |
| First-event prevention | USPSTF April 2022 scope | AHRQ support/member payments; underlying trial money mixed | Attributed framework; no home threshold or efficacy ranking |
| ASCEND and ASPREE | Original randomised human designs | Bayer product support; other public/charitable/commercial routes | Tier 4/D; efficacy estimates excluded |
| Feeding | Nu-Seals; SPS | Manufacturer label; SPS study/contributor gaps | Clinician resolves product/infant differences |
Aspirin names and formulations
Nu-Seals, Nu-Seals Cardio and PostMI are reviewed UK names. This delayed-release secondary-prevention product is unsuitable for short-term pain relief. UK record.
The reviewed US low-strength Ecotrin record is an OTC pain-reliever label. A small tablet strength does not itself establish the UK cardiovascular licence. US product record.
England recorded 20,265,374 aspirin community prescription items in 2025/26, BNF code 0209000A0. Original substance row.
Items are not patients, indications, benefit or OTC purchases. Hospital-issued community-dispensed prescriptions are included; hospital dispensary supplies are not. This is not worldwide popularity. Counting scope.
Check ingredients and local directions with the pharmacist; combination products need separate review. See Antiplatelet Medicines for drug-class and stent context.
Platelets, pain and the limits of mechanism
The professional record describes irreversible platelet cyclo-oxygenase inhibition and reduced thromboxane-mediated platelet aggregation. That antiplatelet mechanism is different from anticoagulant therapy. Professional mechanism.
FDA describes aspirin as reducing platelet clumping. Suspected heart attack requires immediate emergency care; aspirin self-treatment must not delay it. Emergency priority.
A mechanism can explain why a clinician considers a medicine without telling you whether it is appropriate for your illness. Ask which diagnosis and treatment goal the prescription addresses. A laboratory platelet measurement is not the same as demonstrating fewer serious events, and it cannot identify your personal benefit or bleeding probability. This review does not use a mechanism to rank brands, calculate a dose or recommend swapping anticoagulants for aspirin.
Primary versus secondary cardiovascular prevention
The April 2022 US task-force recommendation concerns starting treatment in people without known cardiovascular disease. It calls for selective shared decisions, not routine first-event prevention. Its starting-treatment guidance is not an instruction to stop prescribed secondary prevention. Recommendation scope.
Separate two consultation questions: “Why was aspirin prescribed after my diagnosis or procedure?” and “Would starting it now prevent a first event?” Those questions require different evidence and clinical histories. Take the original discharge or specialist letter to a review if the reason for treatment is unclear; do not reinterpret a headline about healthy volunteers as a change to that letter.
Ask the prescriber to explain the intended outcome, important alternatives, bleeding history and review plan. A guideline recommendation is attributed clinical context here. Its underlying trial results do not become financially independent because a public task force reviews them. No age, risk-score threshold, dose or treatment-duration calculator is provided.
Recovery, lifestyle and supplement claims
NHS advice supports smoking cessation, balanced eating, appropriate activity and management of cholesterol, pressure and weight. Following a heart attack, rehabilitation supports recovery; this does not establish a supplement substitute for prescribed therapy. Recovery and prevention context.
Bring the names and ingredient labels of products marketed for “circulation,” pain, sleep or heart health to the medicine review. A testimonial or an effect on a clotting test cannot establish that a supplement duplicates this prescription. No independently cleared supplement replacement is established in the evidence reviewed here.
Ask the care team how your rehabilitation, preventive medicines and symptom plan fit together. The useful outcome of that conversation is a clear plan and named follow-up service, rather than a shopping list. An activity goal copied from a general prevention page should not become a requirement during an acute illness. This guide does not compare supplement brands or turn food advice into a treatment dose.
ASCEND and ASPREE: original methods and funding
ASCEND randomised UK adults with diabetes but no evident cardiovascular disease, after a placebo run-in. It compared aspirin with placebo and assessed serious vascular events and major bleeding. The published oversight statement reports manufacturer product and packaging support. Original 2018 design.
ASPREE studied selected healthy older adults in Australia and the US. Its primary endpoint combined death, dementia and persistent physical disability; it was not simply a heart-attack endpoint. Bayer supplied aspirin and placebo. Original 2018 design.
Both studies are Tier 4/D under this review’s funding rule; their efficacy estimates are excluded.
Trial randomisation and blinded analysis are methodological strengths that need their own appraisal. They do not change who supplied the treatment. A selected primary-prevention population also cannot directly answer every secondary-prevention question. Excluding sponsored estimates from an independent verdict does not demonstrate that an existing prescription is ineffective; it identifies the limit of this review. No personal event probability or cancer-prevention claim is derived from these papers.
Bleeding, allergy and emergency warning signs
The current Nu-Seals leaflet instructs stopping the product and obtaining immediate medical advice for unusual bleeding or allergy. It lists black stools, blood in vomit/urine, coughing blood and breathing symptoms. Immediate product warning.
Vomiting blood with faintness, confusion, abdominal pain, black stools or feeling unwell requires emergency help. If vomiting has stopped without other symptoms, seek urgent GP/NHS 111 assessment. Emergency versus urgent care.
Throat/tongue swelling, swallowing difficulty, severe breathing difficulty or collapse needs the local emergency service immediately (999 in the UK). A rash need not be present. Airway emergency.
Chest pressure spreading to the arm, neck or jaw, severe breathlessness or abnormal responsiveness requires emergency help. Follow the dispatcher’s instructions; do not delay for a medicine search. Cardiac warning signs.
Urgent warnings override routine continuity advice; bringing the pack must not delay care.
Interactions, painkillers and duplicate ingredients
Anticoagulants, other antiplatelets, NSAIDs, steroids and SSRIs can increase bleeding risk; methotrexate has dose-dependent toxicity restrictions. Kidney-related combinations also need review. Selected interaction framework.
Ibuprofen may interfere with preventive aspirin’s antiplatelet action. FDA advises contacting the clinician about the combination. Do not construct a universal safe spacing rule from this advisory. Interaction advice.
Include prescribed drugs, recently stopped treatment, occasional painkillers, supplements and combination cold or headache products in the list you show the pharmacist. Record the ingredients rather than only the brand names. A professional may need to choose an alternative or arrange monitoring; this page cannot decide which medicine you should change.
A deliberately prescribed combination is different from accidentally duplicating aspirin. If several teams prescribe treatment, identify who coordinates the complete list. For planned dental work or surgery, give that list to both the procedural and prescribing teams and obtain one clear agreed instruction. This guide provides no home dual-antiplatelet or stop/restart schedule.
Children, pregnancy and feeding
Previous aspirin/NSAID-triggered asthma or allergy, active/recurrent ulcer or bleeding, severe kidney/liver disease and selected bleeding disorders can make treatment unsuitable. Other risks require individual assessment. Contraindications and cautions.
Do not give aspirin to children under 16 unless prescribed. Persistent vomiting, drowsiness or behavioural change after illness needs urgent assessment; confusion, seizure or impaired response is an emergency. Mention aspirin exposure. Child safety.
NHS distinguishes prescribed low-dose pregnancy use from analgesic use. Do not start or change it without the obstetric team. Pregnancy distinction.
Nu-Seals prohibits breastfeeding; confirm the preparation with the prescriber. Product restriction.
SPS allows selected cautious low-dose use for full-term healthy infants with monitoring. Fever or viral symptoms in the infant require prompt specialist contact to arrange a safe feeding/treatment plan; no universal home-stop rule follows. Limited specialist context.
Resolve label/advice differences with the prescribing team; limited infant evidence does not establish universal safety.
Taking aspirin and procedures
For routine Nu-Seals use, follow the prescribed directions and swallow whole; its leaflet distinguishes supervised initial treatment. Do not independently crush or chew it, and do not double a missed dose. Preparation instructions.
SPS describes dispersible aspirin as a different licensed formulation. Swallowing problems require an individual formulation assessment; not every tablet can be handled the same way. Formulation assessment.
For excess aspirin, contact a pharmacist immediately, or NHS 111 if unavailable. Intentional overdose needs urgent help even without symptoms. Excess-dose advice.
Too many Nu-Seals tablets: go to A&E or contact a doctor immediately. Overdose instruction.
Keep the written prescription and current pack leaflet together. Ask what to do after missed treatment, a new symptom, admission or a planned procedure. Do not create a loading dose, taper, washout interval or restart date from another person’s plan. Ensure the agreed instructions identify which preparation is being used and who will review the decision.
Human evidence limits and reporting concerns
MHRA Yellow Card accepts suspected medicine problems. Reporting is separate from urgent care and does not establish causation. Reporting service.
Animal, laboratory and simulated findings are not accepted here as proof of clinical efficacy or feeding safety. No comparative efficacy ranking has been established by the selected conflict-screened evidence. A regulatory licence and care recommendation describe a professional role; they are not a fully independent comparison of all treatments.
For a research claim, ask whether the people studied resemble the patient, whether the outcome mattered clinically, how competing harms were measured and whether the complete funding chain was reported. Check the study’s original paper rather than only an institutional summary. These questions support a discussion with the clinician; they do not authorize a medicine change.
Funding and source roles
Research funding at a glance
43 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
The source-specific map separates documented institutional funding from disease-page payments and trial sponsorship. Unknown allocations remain unknown. A public agency, charity or academic address does not by itself establish independent treatment efficacy.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHS aspirin | National website funding policy. Contributor/page/study interests unclosed. | United Kingdom; national NHS website. | Tier 2; public context, provisional | B provisional. July 3, 2026. Educational context; efficacy not cleared. |
| NHS anaphylaxis | Shared national NHS website route below. Contributor/page/study interests unclosed. | United Kingdom; national NHS website. | Tier 2; public context, provisional | C provisional. June 21, 2023; review overdue June 2026. Educational context; efficacy not cleared. |
| NHS vomiting blood | Shared national NHS website route below. Contributor/page/study interests unclosed. | United Kingdom; national NHS website. | Tier 2; public context, provisional | B provisional. August 18, 2025. Educational context; efficacy not cleared. |
| NHS Reye’s syndrome | Shared national NHS website route below. Contributor/page/study interests unclosed. | United Kingdom; national NHS website. | Tier 2; public context, provisional | C provisional. September 14, 2023; review overdue September 2026. Educational context; efficacy not cleared. |
| NHS heart attack | Shared national NHS website route below. Contributor/page/study interests unclosed. | United Kingdom; national NHS website. | Tier 2; public context, provisional | B provisional. March 31, 2026. Educational context; efficacy not cleared. |
| Nu-Seals SmPC, September 2026 | Alliance Pharmaceuticals Ltd holder. Group accounts. | United Kingdom; Chippenham holder. | Tier 4; manufacturer source | D. Product restrictions; efficacy excluded. |
| Nu-Seals patient leaflet, August 2026 | Alliance holder; Chanelle Medical Unlimited Company, Loughrea, Ireland listed maker. Shared commercial routes below; actual supplied-pack plant unverified. | United Kingdom leaflet; Irish listed manufacturer. | Tier 4; manufacturer source | D. Selected administration, bleeding/allergy and overdose cautions. |
| GL aspirin professional record, August 2026 | G.L. Pharma GmbH holder; Own commercial business. | Austria holder; United Kingdom product record. | Tier 4; manufacturer source | D. Selected mechanism, contraindications and interactions; efficacy excluded. |
| Ecotrin US Drug Facts, January 2025 | Medtech Products Inc labeler/packager; Parent subsidiary record. Public hosting separate below. | United States OTC label; pack factory unverified. | Tier 4; manufacturer source | D. Pain-reliever listing/warnings; not UK cardiovascular licence or stock proof. |
| FDA aspirin questions and answers | Regulator finances. Exact page/contributor/trial allocations unclosed. | United States; FDA/HHS. | Tier 3; regulatory context, provisional | B provisional. Actual body read; revision date unverified, historical trial estimates excluded. |
| FDA aspirin and ibuprofen | Shared public-budget/industry-fee route below; exact page and underlying-study money unclosed. | United States; FDA/HHS. | Tier 3; regulatory context, provisional | B provisional. Interaction advisory; no universal safe combination or timing formula. |
| USPSTF aspirin recommendation, April 2022 | Congress-mandated AHRQ support; member honoraria/travel reported. Underlying trials not financially cleared by this review. | United States; AHRQ support, Rockville, Maryland. | Tier 2; guideline context, provisional | B provisional. Selected primary-prevention framework; named outside interests/register incomplete, efficacy estimates excluded. |
| USPSTF disclosure page | Public task-force route; current page under review, not a complete member financial register. | United States; exact page allocation unclosed. | Tier 3; disclosure-process source | B provisional. Actual access limitation read; no clean-author inference. |
| AHRQ task-force support | Statutory administrative/research/technical support. Complete current fiscal receipts, gifts and recommendation allocation unclosed. | United States; federal AHRQ/HHS, Rockville, Maryland. | Tier 3; institutional self-report | B provisional. Support route, not a current appropriation ledger or trial clearance. |
| SPS antiplatelets and breastfeeding | Service commissioning. Exact host, contributor and original-study funding unclosed. | United Kingdom NHS service. | Tier 2; clinical context, provisional | B provisional. July 2023; full-term healthy infants only, very limited evidence; bibliography not retrieved. |
| SPS antiplatelet formulations | Shared commissioning route below; exact host, contributor and study allocations unclosed. | United Kingdom NHS service. | Tier 2; clinical context, provisional | B provisional. June 2024; selected dispersible administration only. |
| ASCEND original trial, 2018 | BHF; Bayer aspirin/placebo and packaging; Solvay/Abbott/Mylan factorial products/packaging; Oxford CTSU MRC/BHF/CRUK support. | United Kingdom trial/Oxford; Bayer Germany/US; other historic jurisdictions unclosed. | Tier 4; manufacturer-supported trial | D. Original methods/support read; separate 2018 author forms inaccessible. Efficacy excluded despite reported analysis independence. |
| ASPREE original trial, 2018 | NIH NIA/NCI, Australian NHMRC, Monash/Victorian Cancer Agency; Bayer supplied products. Nelson/Tonkin/Donnan report Bayer interests; Shah institutional commercial trials. | United States/Australia trial; German Bayer supply. | Tier 4; manufacturer-supported trial | D. Full published funding/COI read; separate forms and complete backer ledgers unclosed. Efficacy excluded. |
| ASCEND 2022 dated disclosures | Bayer products/funds plus public/charitable grants; Armitage/Bowman/Collins Medicines Company and Novartis grants; Mafham Novo Nordisk; other commercial grants declared. | United Kingdom Oxford; complete grant-payer/beneficial-owner chains unclosed. | Tier 4; supported study, financial-only | D. Full published declarations read. Staff personal-payment policy does not remove grants; 2022 is not 2018 payment proof. |
| Alliance annual report, 2024 | Medicine/consumer-health sales and outsourced manufacture; Alliance Pharmaceuticals Ltd listed wholly owned at that reporting date. | England/Wales; Avonbridge House, Bath Road, Chippenham. | Tier 4; seller financial record | D. Selected actual accounts/ownership notes; dated before later transaction, no ingredient allocation. |
| Alliance company RNS, May 14, 2025 | Effective acquisition by Aegros Bidco, indirectly DBAY Affiliates/ERES IV Fund. Complete investors and later changes unclosed. | United Kingdom transaction; investor jurisdictions not all closed. | Tier 4; company financial statement | D. Company-authored RNS replica; completed transaction, not a current ultimate-beneficiary census. |
| DBAY own contact | Investment adviser named in transaction; complete fee income, fund investors and product allocation unclosed. | Isle of Man; 5–11 St Georges Street, Douglas; separate UK office. | Tier 4; investor institutional source | D provisional. Actual own jurisdiction/contact; no inferred trial or page payment. |
| GL Pharma own business | Commercial medicine/manufacture/distribution routes and family management history; full present beneficial ownership/audited ledger unclosed. | Austria; separate imprint below. | Tier 4; seller institutional source | D provisional. Footer preparation November 2023; copyright is not a new audit date. |
| GL Pharma imprint | Company register and named management; not a revenue or grant ledger. | Austria; G.L. Pharma GmbH, Lannach; court Graz, register 61985f. | Tier 4; seller corporate record | D. Own registered identity; exact supplied medicine plant unverified. |
| Prestige FY2026 Form 10-K | Public shareholders; branded OTC wholesale/retail/e-commerce sales, marketing and third-party manufacturing routes. Exact aspirin payments unclosed. | United States; Delaware incorporation, 660 White Plains Road, Tarrytown, New York. | Tier 4; seller financial record | D. Selected company-filed SEC business/accounts; reporting year ended March 31, 2026. |
| Prestige FY2026 subsidiaries | Medtech Products Inc listed as direct/indirect group subsidiary. Exact holding percentage and product-budget allocation unclosed. | United States; listed Medtech jurisdiction Delaware. | Tier 4; seller corporate record | D. Actual company-filed subsidiary table; not manufacturing-site or branded-stock verification. |
| Chanelle own business/contact | Human/veterinary generic development/manufacturing business. Full audited revenue and ingredient allocation unclosed. | Ireland; Dublin Road, Loughrea, County Galway. | Tier 4; manufacturer source | D provisional. Own business/contact, not therapeutic evidence or actual pack-factory verification. |
| Exponent Chanelle portfolio | April 2024 acquisition; current Fund IV/V investment listed, deal value undisclosed. Full fund-investor/fee ledger unclosed. | United Kingdom; 30 Broadwick Street, London; Irish investment. | Tier 4; investor financial source | D provisional. Own actual portfolio; no historic aspirin-trial or label payment assigned. |
| Bayer Consumer Health report, 2025 | Commercial consumer-health sales, including Pain & Cardio category; marketing expenditure. Exact aspirin/trial allocation absent. | Germany group; separate location record below. | Tier 4; seller financial source | D. Actual own division report; current revenue does not establish each historic payment. |
| Bayer annual-report imprint | Bayer AG publisher/holding company with worldwide subsidiaries; not a complete trial-funder ledger. | Germany; 51368 Leverkusen. | Tier 4; seller institutional record | D. March 4, 2026 publication; corporate location, not all manufacturing sites. |
| BHF own 2025/26 financial summary | Legacies, fundraising, retail/other, investment/charitable income. Named donor-to-trial allocations unclosed; full linked report inaccessible. | United Kingdom; Greater London House, 180 Hampstead Road, London. | Tier 3; charity financial self-report | B provisional. Actual income/contact body; charitable status does not clear commercial trial supply. |
| England PCA substances, 2025/26 | Agency accounts. Exact statistics allocation/interests unclosed. | England community dispensing. | Tier 2; public statistics, provisional | B provisional. Actual raw row/cells checked; items do not prove benefit. |
| PCA methodology, June 2026 | Shared NHSBSA institutional route below; exact programme allocation unclosed. | United Kingdom; England dataset. | Tier 2; public definitions, provisional | B provisional. Counting scope, not worldwide prescribing. |
| MHRA Yellow Card | Regulator accounts. Exact reporting-service allocation/interests unclosed. | United Kingdom regulator. | Tier 3; reporting context, provisional | B provisional. Suspected events; reporting cannot replace treatment or prove causation. |
| NHSBSA accounts, 2025/26 | DHSC Parliamentary funding plus operating service/contract income; student-support receipts separately treated. Exact PCA allocation not identified. | United Kingdom; Newcastle upon Tyne. | Tier 3; own financial report | B provisional. Statutory accounts; selected funding notes read. Institutional route only. |
| NHS content policy | DHSC website funding stated; no advertising/corporate sponsorship; contributor declarations required. Policy reviewed 2022, review due 2025. | United Kingdom; national NHS website. | Tier 3; own policy | B provisional. Public accountability; overdue policy review and public contributor-register gaps. No trial clearance. |
| SPS service commissioning | NHS England commissioning with nine host trusts/subcontractors. Published arrangements run to 31 March 2026; renewal and individual provider money unclosed. | United Kingdom; distributed providers, no single HQ verified. | Tier 3; own service statement | B provisional. Contract disclosure; dated coverage does not clear each author/page. |
| NHS England accounts, 2025/26 | DHSC grant-in-aid principally; additional service, research and consolidated charge/other income. Parent and consolidated routes differ; SPS allocation unidentified. | United Kingdom; Leeds contact address. | Tier 3; own financial report | B provisional. Selected notes read; commissioner finances do not replace host-trust ledgers. |
| MHRA accounts, 2025/26 | DHSC grant-in-aid plus statutory industry fees, customer/service income, research grants and biological-standard sales. | United Kingdom; London/Canary Wharf and South Mimms sites. | Tier 3; own financial report | B provisional. Selected current income notes read; exact safety-alert allocation unclosed. |
| NLM FY 2027 justification | FY 2026 enacted funding distinguished from FY 2027 request. Institutional grants/contracts/intramural routes; DailyMed allocation and individual gifts unclosed. | United States; Bethesda NIH library. | Tier 3; own budget report | B provisional. Selected actual budget table read; public hosting does not make labels independent. |
| NLM appropriations index | Congressional justification index; 2026 consolidation described as a proposal. Current 2027 original separately read above. | United States; 8600 Rockville Pike, Bethesda. | Tier 3; own institution record | B provisional. Location/index only; no completed restructuring inferred. |
| NIH gift-administration policy | Conditional/unconditional gift authority with conflict checks; supplementary routes include authorised foundation transfers. Authority does not establish a named NLM donation. | United States; NIH-wide policy. | Tier 3; own financial policy | B provisional. Actual policy read; donor receipts and exact medicine-page allocations unclosed. |
| FDA FY2026 operating plan | Public budget authority and regulated-industry fees, including human drugs/biologics. No exact aspirin-page/application amount assigned. | United States; FDA/HHS, Silver Spring, Maryland. | Tier 3; regulator financial self-report | B provisional. Actual five-page plan, selected fiscal routes; accountability and policy/fee incentives. |
Frequently asked questions
Is preventive aspirin interchangeable with pain treatment? No. Purpose and preparation differ. NHS distinctions.
Does a coating eliminate bleeding risk? No. The reviewed coated Ecotrin product still carries a serious bleeding warning. Coating is not a personal safety guarantee. Actual warning.
Should everyone take aspirin to prevent a first heart attack? No. The US recommendation concerns selected primary prevention; it does not replace review of prescribed secondary prevention. Actual scope.
Can I take aspirin while breastfeeding? Arrange an individual professional review of the preparation, indication and infant. SPS advice is limited to full-term healthy infants and very limited evidence. Scope and evidence limits.
Sources and funding notes
Dated product records do not prove local stock. Original 2018 trial PDFs supplied selected methods and published financial text; separate author forms were inaccessible. The 2022 Oxford declaration is later financial context, not proof of a 2018 payment. Complete historical backer ledgers remain unclosed. SPS feeding bibliography was not retrieved. Institutional policy, gift authority and company accounts do not establish exact page payments or clear underlying trials.
- NHS aspirin — Purpose, selected pregnancy and excess-dose advice
- NHS anaphylaxis — Airway emergency recognition
- NHS vomiting blood — Bleeding emergency versus urgent assessment
- NHS Reye’s syndrome — Children’s cautions and urgent symptoms
- NHS heart attack — Emergency recognition, recovery and prevention context
- Nu-Seals SmPC, September 2026 — Product and jurisdiction boundaries
- Nu-Seals patient leaflet, August 2026 — Patient taking and safety instructions
- GL aspirin professional record, August 2026 — Single-ingredient professional context
- Ecotrin US Drug Facts, January 2025 — US formulation and safety boundary
- FDA aspirin questions and answers — Supervised prevention and emergency priority
- FDA aspirin and ibuprofen — Painkiller interaction review
- USPSTF aspirin recommendation, April 2022 — Primary versus secondary prevention scope
- USPSTF disclosure page — Named-member financial access gap
- AHRQ task-force support — Guideline backer role
- SPS antiplatelets and breastfeeding — Specialist feeding framework
- SPS antiplatelet formulations — Swallowing and formulation assessment
- ASCEND original trial, 2018 — Primary-prevention methods and sponsorship
- ASPREE original trial, 2018 — Population, endpoint and financial boundaries
- ASCEND 2022 dated disclosures — Later named-author financial context only
- Alliance annual report, 2024 — Dated holder-group ownership and revenue
- Alliance company RNS, May 14, 2025 — Subsequent documented control
- DBAY own contact — Investor jurisdiction and gaps
- GL Pharma own business — Holder business and ownership limits
- GL Pharma imprint — Holder jurisdiction
- Prestige FY2026 Form 10-K — Labeler parent revenue and location
- Prestige FY2026 subsidiaries — Ecotrin labeler-parent link
- Chanelle own business/contact — Listed maker commercial route
- Exponent Chanelle portfolio — Listed-maker ownership route
- Bayer Consumer Health report, 2025 — Trial-backer commercial incentive
- Bayer annual-report imprint — Backer jurisdiction
- BHF own 2025/26 financial summary — Charitable backer revenue and limits
- England PCA substances, 2025/26 — Ingredient prescribing context
- PCA methodology, June 2026 — Prescribing denominator limits
- MHRA Yellow Card — Safety reporting
- NHSBSA accounts, 2025/26 — Institutional finance
- NHS content policy — Dated website funding policy
- SPS service commissioning — Programme financial route
- NHS England accounts, 2025/26 — Commissioner finance
- MHRA accounts, 2025/26 — Safety regulator finance
- NLM FY 2027 justification — Label-host institution finance
- NLM appropriations index — Host location and budget provenance
- NIH gift-administration policy — Gift authority, not receipt
- FDA FY2026 operating plan — Regulator financial provenance
Educational research reviewed 4 October 2026. Diagnosis and treatment require a qualified clinician; this article does not provide an individual prescription or replace urgent assessment.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.